EDUCATION

Medical School

  • Albert Einstein College of Medicine , 2005 , Bronx , NY

Internship

  • Boston Children's Hospital/Boston Medical Center , 2006 , Boston , MA

Residency

Pediatrics
  • Boston Children's Hospital/Boston Medical Center , Boston , MA

Fellowship

Pediatric Hematology-Oncology
  • Dana-Farber Cancer Institute , 2011 , Boston , MA

PROFESSIONAL HISTORY

I am a Pediatric Oncology physician-scientist with an interest in translational research and a growing expertise in the care of pediatric solid tumor patients. I have followed a unique path, focused initially on the use of imaging to enhance diagnostics and therapeutics in pediatric solid tumor patients, now with an increasing interest in the Ewing sarcoma cell surfaceome and immune environment. My prior work generating a targeted imaging probe to more sensitively and specifically diagnose Ewing sarcoma micro-metastases inspired a growing interest in targeted immunotherapeutics. My subsequent training in cancer immunology, including but not limited to antibody humanization, characterization, and engineering, has generated the skills necessary to pursue novel immunotherapeutics for pediatric patients. In concert with my preclinical training, I have focused on developing clinical solid tumor expertise, recognizing my career goals of becoming a leader in the care of solid tumor patients with a focus on translational research and innovation.

I lead the Dana-Farber/Boston Children’s pediatric Liver Tumor Center, working closely with surgeons, interventional radiologists, and preclinical researchers to bring innovative care to patients with all types of primary liver tumors. I serve as Chair of the Children’s Oncology Group Liver Tumor Committee and work closely with international colleagues affiliated with the Paediatric Hepatic International Tumour Trial (PHITT) and SIOP Liver Tumor Working Group. My unique split between patient care and research has allowed an opportunity to develop and refine skills in teaching medical students, residents and fellows; training laboratory technicians and post-doctoral fellows; and counseling trainees regarding the intricacies relevant to a career in translational research. With continued support from a multidisciplinary team, I hope to bring the power of cancer imaging and immunotherapy to bear on the diagnosis and treatment of pediatric solid tumor patients.

Research Overview

Currently investigating:

  1. Targeted Immunotherapy for Ewing Sarcoma - The long-term goal of this subset of projects is to develop new, targeted diagnostic and therapeutic options for patients with Ewing sarcoma focused on antibody-specific approaches.
  2. Improved Therapies for Pediatric Hepatocellular Carcinoma (HCC) - The over-arching goal of this group of projects is to better understand the genomic phenotype of pediatric hepatocellular carcinomas while identifying therapies, both standard and immonotherapeutic, that will yield improved outcomes. Dr. O'Neill has also authored the HCC arm of the Pediatric Hepatic International Tumors Trial (PHITT).
  3. Clinical Discovery in Pediatric Hepatoblastoma - Dr. O'Neill's interests in pediatric hepatoblastoma include better understanding the kinetics of alpha feto-protein and improving the treatment of patients with high risk disease. She coordinates the international Online Consultation Forum through SIOP which allows physicians worldwide the opportunity to discuss cases of a difficult nature with international experts. Institutionally, Dr. O'Neill heads the DFCI Liver Tumor Program working jointly with surgeons, preclinical researchers, and clinicians to assure a comprehensive patient-care experience.
  4. Oncology/Interventional Radiology Collaborative - The goal of this working relationship is to prioritize interventional techniques for patients with relapsed/refractory solid tumors and to better document our institutional experiences and outcomes utilizing these approaches.


CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Pediatric Hematology and Oncology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Fibrolamellar carcinoma: An entity all its own. Curr Probl Cancer. 2021 Jul 01; 100770. View abstract
  2. Undifferentiated Embryonal Sarcoma of the Liver With Rhabdoid Morphology Mimicking Carcinoma: Expanding the Morphologic Spectrum or a Distinct Variant? Pediatr Dev Pathol. 2021 Jun 14; 10935266211018930. View abstract
  3. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Mar 09. View abstract
  4. A serous borderline ovarian tumour in a transgender male adolescent. Br J Cancer. 2021 02; 124(3):567-569. View abstract
  5. Timely pediatric cancer diagnoses: An unexpected casualty of the COVID-19 surge. Pediatr Blood Cancer. 2020 12; 67(12):e28729. View abstract
  6. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View abstract
  7. Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. Pediatr Blood Cancer. 2020 09; 67(9):e28326. View abstract
  8. A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. Oncologist. 2020 11; 25(11):925-e1603. View abstract
  9. The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database. Pediatr Blood Cancer. 2020 08; 67(8):e28350. View abstract
  10. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. Oncologist. 2020 12; 25(12):e1837-e1845. View abstract
  11. Correction: BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. 2020 Mar; 39(12):2641. View abstract
  12. BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. 2020 03; 39(11):2305-2327. View abstract
  13. a-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer. 2019 10 15; 125(20):3649-3656. View abstract
  14. High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. Clin Cancer Res. 2019 07 15; 25(14):4552-4566. View abstract
  15. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019 05; 20(5):719-727. View abstract
  16. Long-term outcomes of liver transplantation for hepatoblastoma: A single-center 14-year experience. Pediatr Transplant. 2018 Jun 11; e13250. View abstract
  17. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol. 2017 12 01; 3(12):1634-1639. View abstract
  18. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb; 65(2). View abstract
  19. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. J Clin Oncol. 2017 Oct 20; 35(30):3465-3473. View abstract
  20. Hepatocellular Carcinoma in Fanconi-Bickel Syndrome. Pediatr Dev Pathol. 2018 Jan-Feb; 21(1):84-90. View abstract
  21. Unresectable hepatoblastoma: current perspectives. Hepat Med. 2017; 9:1-6. View abstract
  22. Cause and effect: the etiology of pediatric hepatocellular carcinoma and the role for liver transplantation. Pediatr Transplant. 2016 11; 20(7):878-879. View abstract
  23. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 12; 130(3):495-503. View abstract
  24. Post-transplant lymphoproliferative disorder of the pediatric airway: Presentation and management. Int J Pediatr Otorhinolaryngol. 2016 Jul; 86:218-23. View abstract
  25. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. Clin Cancer Res. 2014 Feb 01; 20(3):678-87. View abstract
  26. Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. . 2011 Dec; 301(6):C1325-43. View abstract
  27. Ludwig's angina following frenuloplasty in an adolescent. Int J Pediatr Otorhinolaryngol. 2009 Sep; 73(9):1313-5. View abstract
  28. Ludwig's angina in the pediatric population. Clin Pediatr (Phila). 2009 Jul; 48(6):583-7. View abstract
  29. Immaturity of IL-18 gene expression and protein production in cord blood (CB) versus peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and function. Br J Haematol. 2005 Jul; 130(2):284-92. View abstract
  30. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005 May-Jun; 28(3):203-11. View abstract
  31. Are there universal parenting concepts among culturally diverse families in an inner-city pediatric clinic? J Pediatr Health Care. 2005 May-Jun; 19(3):142-50. View abstract
  32. Regulation of Ca(2+) signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. Hepatology. 2002 Aug; 36(2):284-96. View abstract
  33. Regulation of the type III InsP(3) receptor by InsP(3) and calcium. Biochem Biophys Res Commun. 2002 Jun 14; 294(3):719-25. View abstract
  34. The type II inositol 1,4,5-trisphosphate receptor can trigger Ca2+ waves in rat hepatocytes. Gastroenterology. 2002 Apr; 122(4):1088-100. View abstract
  35. A primitive ATP receptor from the little skate Raja erinacea. J Biol Chem. 2000 Sep 29; 275(39):30701-6. View abstract
  36. Primitive organization of cytosolic Ca(2+) signals in hepatocytes from the little skate Raja erinacea. J Exp Biol. 1999 Nov; 202(Pt 22):3049-56. View abstract